関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | HCID 178418203 | HCID 178418203 | — |
| 反応物 | HCID 178418222 | HCID 178418222 | — |
| 試薬 | Cesium carbonate | HCID 10796 | — |
| 触媒 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 触媒 | Di-tert-butyl(2',4',6'-tris(propan-2-yl)-(1,1'-biphenyl)-2-yl)phosphane | HCID 11618717 | — |
| 溶媒 | 1,4-Dioxane | HCID 31275 | — |
| 生成物 | N-[5-[[3-cyano-7-(oxetan-3-ylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-cyclopropyl-4-fluorophenyl]acetamide | HCID 72164290 | 23.91% |
反応手順
dioxane (4 mL) was adde to the mixture of N-(5-amino-2-cyclopropyl-4-fluorophenyl)acetamide (100 mg, 0.48 mmol), 5-chloro-7-(oxetan-3-ylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (132 mg, 0.53 mmol),cesium carbonate (469 mg, 1.44 mmol), Pd2(dba)3 (44.0 mg, 0.05 mmol), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (40.8 mg, 0.10 mmol) in 5 ml microwave vial. N2 flow was bubbled through for 3 mins. Then the reaction solution was sealed with cap, degassed and refilled with argon 3 times. The resulting solution was heated at 140°C for 40 mins in microwave. LC/MS showed desired product as major peak. After the crude solution was concentrated, the crude residue was purified by chromatography (100% EtOAc to 3% MeOH in EtOAc). N-(5-(3-cyano-7-(oxetan-3-ylamino)pyrazolo[1,5-a]pyrimidin-5-ylamino)-2-cyclopropyl-4-fluorophenyl)acetamide (48.4 mg, 23.91 %) was obtained.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-7d21d2aa9b9646bf85b8f593faa79359 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|